CD274 and metastatic neoplasm: Almost all of these studies evaluated the concordance rate of PD-L1 expression between primary and metastatic tumor sites in stage IV NSCLC and report a high concordance for tumors with a PD-L1 TPS of <1% or ≥50% (32).